Payment overview · 2025
General Payments
$748.45
38 reported records · 15 companies
Healthcare provider profile · identity verified
Ronald Wayne Orso, MD
Allopathic & Osteopathic Physicians|Obstetrics & Gynecology · BIRMINGHAM, AL · NPI 1689631574
Verified facts
What the public records show
CMS Open Payments records show Ronald Wayne Orso, MD received $748.45 in general payments during 2025 across 38 reported records.
Sumitomo Pharma America, Inc. accounted for 25.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Myrbetriq by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $192.81 | 25.8% | 13 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $144.58 | 19.3% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $92.39 | 12.3% | 4 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $51.10 | 6.8% | 2 | 2025 |
| Exeltis, USA Inc. | Unresolved — no canonical attribution shown | $44.88 | 6.0% | 2 | 2025 |
| Sage Therapeutics, LLC | Unresolved — no canonical attribution shown | $41.53 | 5.5% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $32.44 | 4.3% | 2 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $28.44 | 3.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.30 | 2.7% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.20 | 2.7% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $17.43 | 2.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.24 | 2.2% | 1 | 2025 |
| CooperSurgical, Inc. | Unresolved — no canonical attribution shown | $15.90 | 2.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.56 | 2.1% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $14.65 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $648.46 | 37 |
| Education | $99.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $156.30 | 11 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $92.39 | 4 | 2025 |
Source payment records
|
|||||
| SLYND Normalized: slynd |
Drug | Exeltis, USA Inc. | $44.88 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $44.59 | 3 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Sage Therapeutics, LLC | $41.53 | 2 | 2025 |
Source payment records
|
|||||
| SURGIFLO Hemostatic Matrix Normalized: surgiflo hemostatic matrix |
Device | Ethicon US, LLC | $36.62 | 1 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $36.51 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| FLUENT FLUID MANAGEMENT SYSTEM Normalized: fluent fluid management system |
Device | Hologic Sales and Service, LLC | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| MYOSURE TISSUE REMOVAL DEVICE Normalized: myosure tissue removal device |
Device | Hologic Sales and Service, LLC | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| NOVASURE Normalized: novasure |
Device | Hologic Sales and Service, LLC | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| Kyleena Normalized: kyleena |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| Lynkuet Normalized: lynkuet |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| Mirena Normalized: mirena |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| Endosee Normalized: endosee |
Device | CooperSurgical, Inc. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.56 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.56 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| Enseal Normalized: enseal |
Device | Ethicon US, LLC | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| Harmonic Normalized: harmonic |
Device | Ethicon US, LLC | $14.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Estradiol | Estradiol | 370 | 159 |
| Risedronate Sodium | Risedronate Sodium | 114 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 108 | 34 |
| Simvastatin | Simvastatin | 84 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 24 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 68 | 43 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 61 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 57 | 50 |
| Premarin | Estrogens, Conjugated | 50 | 12 |
| Valacyclovir | Valacyclovir Hcl | 49 | 22 |
| Alendronate Sodium | Alendronate Sodium | 44 | suppressed |
| Myrbetriq | Mirabegron | 44 | 11 |
| Meloxicam | Meloxicam | 42 | 13 |
| Trazodone Hcl | Trazodone Hcl | 42 | 18 |
| Lisinopril | Lisinopril | 39 | 15 |
| Atorvastatin Calcium | Atorvastatin Calcium | 34 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 32 | 32 |
| Fluconazole | Fluconazole | 31 | 23 |
| Raloxifene Hcl | Raloxifene Hcl | 31 | suppressed |
| Metformin Hcl | Metformin Hcl | 28 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 25 |
| Omeprazole | Omeprazole | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 22 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Yuvafem | Estradiol | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 19 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 19 | 15 |
| Estradiol-Norethindrone Acetat | Estradiol/Norethindrone Acet | 18 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 15 | suppressed |
| Losartan Potassium | Losartan Potassium | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 11 |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Larin Fe | Norethindrone-E.Estradiol-Iron | 13 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $748.45 · 38 records | Sumitomo Pharma America, Inc. | ABRYSVO, ACCRUFER, APTIMA, Endosee, Enseal, FLUENT FLUID MANAGEMENT SYSTEM, GEMTESA, Harmonic, Kyleena, Lynkuet, MYFEMBREE, MYOSURE TISSUE REMOVAL DEVICE, Mirena, NEXPLANON, NOVASURE, QULIPTA, Qelbree, SLYND, SURGIFLO Hemostatic Matrix, UBRELVY, Veozah, ZURZUVAE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error